FCER2 and neoplasm: TLS status, evaluated by trained pathologists on pre-treatment tumor samples, was found in 49.5% (252/509) of cases, with 20.8% characterized as immature TLSs (iTLSs) and 28.7% as mTLSs, identified by the presence of CD23+ follicular dendritic cells (Figure 1A).